Skip to main content
Vaibhav Upadhyay, MD, Pulmonology, San Francisco, CA

VaibhavUpadhyayMDPhD(He/Him)

Pulmonology San Francisco, CA

Critical Care Medicine

Physician

Dr. Upadhyay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Upadhyay's full profile

Already have an account?

  • Office

    505 Parnassus Ave
    San Francisco, CA 94143
    Phone+1 415-476-1528

Summary

  • Dr. Vaibhav Upadhyay is an Assistant Professor in Pulmonary and Critical Care at UCSF. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine. He specializes in critical care medicine. He is a physician scientist whose published works can be viewed here: https://www.ncbi.nlm.nih.gov/myncbi/1vKTAkd3asb5k/bibliography/public/

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2018 - 2021
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 2015 - 2018
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2015

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2016 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Publications & Presentations

PubMed

Press Mentions

  • CDC Rates Pfizer Vaccine 66% on Efficacy Scale Against Delta Variant
    CDC Rates Pfizer Vaccine 66% on Efficacy Scale Against Delta VariantOctober 4th, 2021
  • How COVID-19 Variants Could Outsmart Vaccines
    How COVID-19 Variants Could Outsmart VaccinesSeptember 28th, 2021